New TYSABRI® Analysis At American Academy of Neurology Annual Meeting Shows Improved Walking Speed In Significant Number Of MS Patients
5/1/2014 2:58:02 PM
Biogen Idec (NASDAQ: BIIB) today announced that a post hoc analysis of data from the AFFIRM study shows TYSABRI® (natalizumab) significantly increased the proportion of relapsing-remitting multiple sclerosis (RRMS) patients with confirmed improvement in walking speed (CIWS) relative to placebo at two years.
Help employers find you! Check out all the jobs and post your resume.
comments powered by